Evidence map›Paper›PMID 42426445›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Optimized Workflow for Sensitive Detection of Circulating Tumor Cells Using qPCR and Pre-Amplification to Minimize Cross-Contamination.

Eva Obermayr, Robert Zeillinger

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eva ObermayrMolecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. eva.obermayr@muv.ac.at.
Robert ZeillingerMolecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor cells (CTCs) offer valuable insights for cancer treatment, but their small number, low abundance and heterogeneity pose challenges for routine clinical use. The detection of CTCs requires sensitive technologies to overcome the abundance of hematogenous cells. This typically involves enriching the sample to increase the relative amount of CTCs, followed by analytical methods like gene expression profiling. Quantitative PCR (qPCR) has proven useful for assessing CTC heterogeneity and molecular characterization. However, ensuring accurate results requires high CTC abundance and minimal contamination from leukocytes. We developed a workflow using microfluidic CTC enrichment and qPCR to detect specific gene transcripts, utilizing a pre-amplification protocol to enhance the signal. To minimize cross-contamination risks, we employ deoxyuridine triphosphate (dUTP) in the pre-amplification step and a heat-labile uracil-N-glycosylase (UNG) enzyme, which prevents false positives. This approach ensures sensitive, accurate CTC detection while reducing contamination risk, making it a robust method for clinical application.

Indexed as

Neoplastic Cells, CirculatingReal-Time Polymerase Chain ReactionBiomarkers, TumorCell SeparationGene Expression ProfilingHumansWorkflowBiomarkers, TumorCirculating tumor cellsCross-contaminationGene expression analysisLiquid biopsyTargeted pre-amplification

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.